Comment from Natalie Ma

We noticed many of the examples in the draft guidance focus on biologics and cell therapies. Is the guidance intended to be applied only to biologics and cell/gene therapies, or would the Agency also view it as applicable to a small molecule therapy if target and pathway differed between humans and animal models?